Discussion
The approved therapy Uplizna (inebilizumab) may reduce the risk of disease flares in adults with IgG4-related disease (IgG4-RD) who have kidney involvement, according to a new analysis of clinical trial data. The new analysis focuses on a subgroup of patients in the Phase 3 MITIGATE clinical trial…
